H. Lundbeck
Ottiliavej 9, Valby, 2500, Denmark
Overview
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing, and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centers in Denmark and China.
- Total investments
- 3
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Health Care
- Health Diagnostics
- Medical
Investment portfolio
- Naurex
Participated · Series C · Dec 2014
Naurex is a clinical-stage biopharmaceutical company based in Evanston, Ill., that has built a platform to discover drugs that enhance synaptic plasticity via selective modulation of the NMDA receptor. Its lead molecule, GLYX-13, has demonstrated rapid, robust and sustained antidepressant effects in multiple Phase 2 studies and was well-tolerated in clinical proof-of-concept studies. Naurex is proceeding with a GLYX-13 Phase 3 program after completing an end-of-Phase 2 meeting with the FDA and expects Phase 3 to begin in 2015. The company’s next-generation oral candidate, NRX-1074, is in Phase 2 for major depressive disorder and has shown promising preclinical efficacy and early clinical tolerability. Naurex applies its NMDA-focused platform to generate a pipeline of subtype-selective modulators aimed at a range of CNS indications, including depression, traumatic brain injury and neuropathic pain. The company planned to use financing proceeds to support ongoing clinical development of GLYX-13, NRX-1074 and related development activities across its pipeline. Naurex is a clinical-stage company based in Evanston, Illinois, developing drugs that modulate the NMDA receptor for psychiatry and neurology. Its lead program is GLYX-13, an NMDA receptor modulator in development for the treatment of depression. The company is also advancing its second-generation compound NRX-1074 into Phase I and II clinical trials in depression. Naurex plans to further develop its second- and third-generation programs for other CNS disorders. Leadership includes CEO Derek A. Small and executive chairman Bill Gantz, and the company’s programs are based on work by founder Dr. Joseph R. Moskal and colleagues at Northwestern University. Financially, Naurex completed a $38M Series B financing to fund these development programs. Naurex, based in Evanston, IL, is a clinical-stage company focused on therapeutics for psychiatry and neurology. Its lead compound is GLYX-13, a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA receptor. GLYX-13 showed promising antidepressant activity and excellent safety in preclinical studies, results that were confirmed in a Phase I clinical trial. The company plans a Phase II trial targeting patients not achieving an adequate response to current antidepressants. Naurex is also advancing a second-generation GFPA program with multiple molecules showing preclinical proof of concept. The company is led by CEO Derek A. Small and has made recent board appointments including Wilbur (Bill) Gantz as chairman, with Terry Gould and Kenneth Widder joining the board.
Team
No current team members are available.